Print 03 August 2016
Highlights miraDry system to 25,000+ aesthetic practices in the U.S.
SANTA CLARA, Calif., — August 3, 2016 — Miramar Labs, Inc., (OTCQB: MRLB), a global aesthetic company, announced today that the Company’s miraDry® system is featured in a cover story in the July/August edition of The Aesthetic Guide. The miraDry system delivers microwave energy to non-invasively destroy sweat and odor glands in the underarm, and is also approved for permanent hair removal of the underarm. The cover story article, titled “Miramar Labs Creates New Markets with miraWave Therapy,” may be accessed on-line in the current issue of the magazine: http://miinews.com/the‐aesthetic‐guide
The Aesthetic Guide is a bi-monthly print publication serving a readership of over 25,000 aesthetic medical practices in the U.S. Considered the most influential journal in the field of medical aesthetics, THE Aesthetic Guide offers the latest developments in aesthetic medicine as well as comprehensive product comparisons, clinical roundtable discussions and practice development strategies.
“This feature story in The Aesthetic Guide provides another opportunity to expand awareness among aesthetic practitioners and patients of the unique ability of the miraDry system to non- invasively and permanently reduce underarm sweat and hair,” commented Mike Kleine, Chief Executive Officer of Miramar. “The miraDry procedure is backed by robust clinical data and one of the highest patient satisfaction rates in aesthetics. miraDry also provides a strong business proposition for our customers because it supports their practices’ expansion by attracting new patients and is often one of the most profitable procedures within a practice.”
About Miramar Labs:
Founded in 2006, Miramar Labs, Inc., is a global medical device company dedicated to bringing innovative applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that millions of people deal with daily. The miraDry® procedure has an established safety and efficacy profile with over 70,000 patients treated worldwide. Physicians and patients are encouraged to visit www.miramarlabs.com or www.miradry.com for additional information.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.